Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 80 publications
High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinoma.
Journal: Melanoma research
Published: February 04, 2026
Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer.
Journal: NPJ precision oncology
Published: October 07, 2025
Genetic haplotypes in VWA8, OSBPL6, and ADAMTS9-AS2 are associated with immune-related adverse effects in ICI-treated patients with cancer.
Journal: Journal for immunotherapy of cancer
Published: September 22, 2025
A phase Ib/II study of modakafusp alfa alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors.
Journal: Frontiers in oncology
Published: April 30, 2025
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 03, 2025
Antigenic cancer persister cells survive direct T cell attack.
Journal: bioRxiv : the preprint server for biology
Published: April 01, 2025
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.
Journal: The British journal of dermatology
Published: July 30, 2024
Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer.
Journal: JTO clinical and research reports
Published: June 26, 2024
Differences in systemic immune parameters in individuals with lung cancer according to race.
Journal: bioRxiv : the preprint server for biology
Published: June 25, 2024
Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells.
Journal: Journal for immunotherapy of cancer
Published: December 27, 2023
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab.
Journal: NPJ precision oncology
Published: December 06, 2023
Method for estimation of apoptotic cell fraction of cytotherapy using in vivo fluorine-19 magnetic resonance: pilot study in a patient with head and neck carcinoma receiving tumor-infiltrating lymphocytes labeled with perfluorocarbon nanoemulsion.
Journal: Journal for immunotherapy of cancer
Published: May 21, 2023
Last Updated: 09/26/2026